NDANASALPOWDER
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
BAQSIMI (glucagon) by R-Pharm US is receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Approved for hypoglycemia, type 1 diabetes mellitus. First approved in 2019.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BAQSIMI is a nasal powder formulation of glucagon approved in July 2019 for treating severe hypoglycemia in adults and older patients with diabetes. The drug works by binding to glucagon receptors to stimulate glycogen breakdown and glucose release from the liver, rapidly reversing dangerous low blood sugar episodes. As a non-injectable rescue therapy, BAQSIMI offers a needle-free alternative to traditional glucagon emergency kits, improving accessibility and ease of use during hypoglycemic crises.
$0.0BPart D
13.4 years to LOEMechanism of Action
receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect.
Pharmacologic Class:
Antihypoglycemic Agent
Indications (2)
Worked on BAQSIMI at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.